The Role of Cholecystokinin 1 Receptor in Prolactin Inhibited Gastric Emptying of Male Rat.
- Author:
Full Young CHANG
1
;
Ching Liang LU
;
Tseng Shing CHEN
;
Paulus S WANG
Author Information
1. Environmental Heath and Safety Office and Division of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan. changfy@vghtpe.gov.tw
- Publication Type:Original Article
- Keywords:
Cholecystokinin;
Gastric emptying;
Lorglumide;
Prolactin
- MeSH:
Animals;
Cerebral Cortex;
Cholecystokinin;
Gastric Emptying;
Humans;
Hyperprolactinemia;
Injections, Intraperitoneal;
Intestines;
Kidney;
Male;
Mammals;
Peptides;
Pituitary Gland;
Plasma;
Proglumide;
Prolactin;
Radioactivity;
Radioimmunoassay;
Rats;
Stomach;
Transplants
- From:Journal of Neurogastroenterology and Motility
2012;18(4):385-390
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Prolactin (PRL) is essential for the lactating mammals, while cholecystokinin (CCK) does inhibit gastric emptying (GE). Present study attempted to determine whether both peptides interacted on the male rat GE, particularly the role of putative CCK1 receptor. METHODS: Acute hyperprolactinemia of male rats was induced by the intraperitoneal injection of ovine PRL (oPRL) in several divided doses 15 minutes before motility study. Rat chronic hyperprolactinemia was induced by the graft of 2 pituitary glands into the capsule of left kidney, while control rats received cerebral cortex graft only. Motility study was conducted 6 weeks later after graft surgery. Fifteen minutes after the intragastric feeding of radiochromium, rat was sacrificed to measure GE via the distribution of radioactivities within stomach and intestine. Among the CCK1 receptor blocking study using lorglumide, rats were divided to receive the regimens in terms of oPRL-vehicle plus lorglumide-vehicle, oPRL plus lorglumide-vehicle, oPRL-vehicle plus lorglumide and oPRL plus lorglumide. Plasma CCK level was measured using a homemade radioimmunoassay kit. RESULTS: Compared to vehicle treatment, acute hyperprolactinemic rats under highest dose (2.0 mg/kg) of oPRL treatment showed delayed GE (70.6% +/- 3.0% vs 42.1% +/- 6.6%, P < 0.05). Chronic hyperprolactinemic rats under graft surgery also showed inhibited GE (70.5% +/- 1.7% vs 54.5% +/- 4.7%, P < 0.05). Both models finally obtained elevated plasma CCK levels (P < 0.05). Lorglumide itself did not influence GE, however, delayed GE under oPRL treatment was restored following the concomitant lorglumide treatment. CONCLUSIONS: Our study suggests that PRL may delay male rat GE via a mechanism of endogenous CCK activation involving the peripheral CCK1 receptor.
